X4 Pharmaceuticals (XFOR) Expected to Announce Quarterly Earnings on Tuesday

X4 Pharmaceuticals (NASDAQ:XFOR) is expected to release its earnings data before the market opens on Tuesday, March 25th. Analysts expect X4 Pharmaceuticals to post earnings of ($0.17) per share and revenue of $1.07 million for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

X4 Pharmaceuticals Stock Performance

NASDAQ XFOR opened at $0.31 on Monday. The business’s 50 day moving average price is $0.46 and its 200-day moving average price is $0.53. X4 Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $1.60. The company has a market cap of $52.41 million, a P/E ratio of -3.41 and a beta of 0.39. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89.

Insider Buying and Selling at X4 Pharmaceuticals

In related news, CEO Paula Ragan sold 76,473 shares of X4 Pharmaceuticals stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $34,412.85. Following the completion of the sale, the chief executive officer now owns 1,087,386 shares in the company, valued at $489,323.70. This trade represents a 6.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Adam S. Mostafa sold 74,773 shares of the company’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $33,647.85. The disclosure for this sale can be found here. Insiders sold 202,663 shares of company stock worth $91,198 over the last 90 days. Company insiders own 1.62% of the company’s stock.

Institutional Trading of X4 Pharmaceuticals

An institutional investor recently raised its position in X4 Pharmaceuticals stock. Bank of America Corp DE boosted its stake in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 20.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 133,502 shares of the company’s stock after buying an additional 22,485 shares during the period. Bank of America Corp DE owned 0.08% of X4 Pharmaceuticals worth $98,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 72.03% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $1.50 target price on shares of X4 Pharmaceuticals in a research note on Friday, February 7th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.